About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality.

Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology.

Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

S. region. S.

Sales, the RBD is responsible for executing national sales strategies, leading a high-performing team of oncology account managers, and driving regional performance to achieve commercial objectives. The RBD will recruit, develop, and coach a field sales team while fostering strong collaboration with Marketing, Market Access, Medical Affairs, and other cross-functional partners. This leader will serve as the voice of the field by providing customer insights, competitive intelligence, and market feedback to optimize commercial execution.

This role will report to the Head of US Sales.

Responsibilities

: Execute national sales strategies and business plans to achieve regional sales objectives and market share goals. Recruit, develop, coach, and retain a high-performing team of oncology account managers, fostering a culture of accountability, collaboration, and excellence. Lead regional launch readiness and execution, ensuring sales representatives are prepared to effectively promote ivonescimab and deliver a best-in-class customer experience.

Monitor regional sales performance through KPIs, performance metrics, and business analytics; provide ongoing coaching and development to maximize team effectiveness. Develop strategic regional business plans and account strategies to optimize customer engagement and resource deployment. Partner closely with Marketing, Medical Affairs, Market Access, Commercial Operations, and other cross-functional teams to ensure aligned execution of commercial initiatives.

Build and maintain strong relationships with key oncology customers, healthcare systems, and regional stakeholders. Gather and communicate customer insights, competitive intelligence, and market dynamics to inform commercial strategy and continuous improvement.

Oncology Regional Business Director - Chicago